251 related articles for article (PubMed ID: 21460799)
1. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
Wilbertz T; Wagner P; Petersen K; Stiedl AC; Scheble VJ; Maier S; Reischl M; Mikut R; Altorki NK; Moch H; Fend F; Staebler A; Bass AJ; Meyerson M; Rubin MA; Soltermann A; Lengerke C; Perner S
Mod Pathol; 2011 Jul; 24(7):944-53. PubMed ID: 21460799
[TBL] [Abstract][Full Text] [Related]
2. Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer.
Schröck A; Göke F; Wagner P; Bode M; Franzen A; Braun M; Huss S; Agaimy A; Ihrler S; Menon R; Kirsten R; Kristiansen G; Bootz F; Lengerke C; Perner S
PLoS One; 2013; 8(3):e59201. PubMed ID: 23544055
[TBL] [Abstract][Full Text] [Related]
3. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.
Maier S; Wilbertz T; Braun M; Scheble V; Reischl M; Mikut R; Menon R; Nikolov P; Petersen K; Beschorner C; Moch H; Kakies C; Protzel C; Bauer J; Soltermann A; Fend F; Staebler A; Lengerke C; Perner S
Hum Pathol; 2011 Aug; 42(8):1078-88. PubMed ID: 21334718
[TBL] [Abstract][Full Text] [Related]
4. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.
Yuan P; Kadara H; Behrens C; Tang X; Woods D; Solis LM; Huang J; Spinola M; Dong W; Yin G; Fujimoto J; Kim E; Xie Y; Girard L; Moran C; Hong WK; Minna JD; Wistuba II
PLoS One; 2010 Feb; 5(2):e9112. PubMed ID: 20161759
[TBL] [Abstract][Full Text] [Related]
5. Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2.
Brcic L; Sherer CK; Shuai Y; Hornick JL; Chirieac LR; Dacic S
Am J Clin Pathol; 2012 Nov; 138(5):712-8. PubMed ID: 23086772
[TBL] [Abstract][Full Text] [Related]
6. SOX2 Gene Amplification and Overexpression is Linked to HPV-positive Vulvar Carcinomas.
Gut A; Moch H; Choschzick M
Int J Gynecol Pathol; 2018 Jan; 37(1):68-73. PubMed ID: 28700423
[TBL] [Abstract][Full Text] [Related]
7. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
Bass AJ; Watanabe H; Mermel CH; Yu S; Perner S; Verhaak RG; Kim SY; Wardwell L; Tamayo P; Gat-Viks I; Ramos AH; Woo MS; Weir BA; Getz G; Beroukhim R; O'Kelly M; Dutt A; Rozenblatt-Rosen O; Dziunycz P; Komisarof J; Chirieac LR; Lafargue CJ; Scheble V; Wilbertz T; Ma C; Rao S; Nakagawa H; Stairs DB; Lin L; Giordano TJ; Wagner P; Minna JD; Gazdar AF; Zhu CQ; Brose MS; Cecconello I; Ribeiro U; Marie SK; Dahl O; Shivdasani RA; Tsao MS; Rubin MA; Wong KK; Regev A; Hahn WC; Beer DG; Rustgi AK; Meyerson M
Nat Genet; 2009 Nov; 41(11):1238-42. PubMed ID: 19801978
[TBL] [Abstract][Full Text] [Related]
8. Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma.
Schröck A; Bode M; Göke FJ; Bareiss PM; Schairer R; Wang H; Weichert W; Franzen A; Kirsten R; van Bremen T; Queisser A; Kristiansen G; Heasley L; Bootz F; Lengerke C; Perner S
Carcinogenesis; 2014 Jul; 35(7):1636-42. PubMed ID: 24743512
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
10. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
[TBL] [Abstract][Full Text] [Related]
12. SOX2 expression and prognostic significance in ovarian carcinoma.
Pham DL; Scheble V; Bareiss P; Fischer A; Beschorner C; Adam A; Bachmann C; Neubauer H; Boesmueller H; Kanz L; Wallwiener D; Fend F; Lengerke C; Perner S; Fehm T; Staebler A
Int J Gynecol Pathol; 2013 Jul; 32(4):358-67. PubMed ID: 23722508
[TBL] [Abstract][Full Text] [Related]
13. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.
Sholl LM; Barletta JA; Yeap BY; Chirieac LR; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1193-8. PubMed ID: 20631605
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma.
Iijima Y; Seike M; Noro R; Ibi T; Takeuchi S; Mikami I; Koizumi K; Usuda J; Gemma A
Int J Oncol; 2015 Feb; 46(2):505-12. PubMed ID: 25384882
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH.
Russell PA; Yu Y; Young RJ; Conron M; Wainer Z; Alam N; Solomon B; Wright GM
Mod Pathol; 2014 Dec; 27(12):1621-31. PubMed ID: 24762544
[TBL] [Abstract][Full Text] [Related]
16. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.
Hussenet T; Dali S; Exinger J; Monga B; Jost B; Dembelé D; Martinet N; Thibault C; Huelsken J; Brambilla E; du Manoir S
PLoS One; 2010 Jan; 5(1):e8960. PubMed ID: 20126410
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
18. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.
Li Q; Liu F; Zhang Y; Fu L; Wang C; Chen X; Guan S; Meng X
Oncotarget; 2016 Jun; 7(23):34520-31. PubMed ID: 27150062
[TBL] [Abstract][Full Text] [Related]
19. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.
Bayo P; Jou A; Stenzinger A; Shao C; Gross M; Jensen A; Grabe N; Mende CH; Rados PV; Debus J; Weichert W; Plinkert PK; Lichter P; Freier K; Hess J
Mol Oncol; 2015 Oct; 9(8):1704-19. PubMed ID: 26040981
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic down-regulation of SOX2 is an independent poor prognostic factor for hypopharyngeal cancers.
Avincsal MO; Jimbo N; Fujikura K; Shinomiya H; Otsuki N; Morimoto K; Furukawa T; Morita N; Maehara R; Itoh T; Nibu KI; Zen Y
Histopathology; 2018 Apr; 72(5):826-837. PubMed ID: 29143365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
